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EXPRESSION OF OXIDATIVE STRESS RELATED GENES IN CORTICAL 
TISSUE OF PATIENTS WITH POST-TRAUMATIC STRESS DISORDER 
ANTHONY COLE RESTAINO 
ABSTRACT 
  
Background: In recent years, studies have increasingly pointed to a number of different 
mechanisms that potentially form the foundation for the neurodegenerative pathology 
seen in Post-Traumatic Stress Disorder (PTSD). One such mechanism is neural damage 
due to oxidative stress. This study attempted to identify significantly altered expression 
levels of particular genes of interest between PTSD and control groups, as well as 
between PTSD samples and samples exhibiting commonly seen PTSD comorbidities, 
major depressive disorder (MDD), and depressive disorder not otherwise specified 
(DepNOS). The genes of interest being pursued in the study encompass the production of 
reactive oxygen species, such as inflammatory response mechanisms, the processes that 
control the removal of reactive oxygen species (ROS), and genes that are activated in 
response to oxidative stress. Other genes of interest involve factors important in the 
structural integrity of the prefrontal cortex, such as junction proteins, the blood-brain 
barrier, such as aquaporins, and neuronal integrity. These genes were included due to the 
evidence of structural degeneration in PTSD patients. A total of 54 genes were tested in 
all four groups.  
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Objectives: To identify and determine genetic differences amongst individuals with 
PTSD in comparison to non-PTSD sufferers, and sufferers of common PTSD 
comorbidities.  
Methods: The expression levels of the genes of interest were measured using quantitative 
polymerase chain reaction (qPCR) techniques. RNA is extracted and collected from 
tissues samples of deceased military PTSD patients from the prefrontal cortex. The 
prefrontal cortex derived RNA is used as the experimental samples, due to the prevalence 
of the pathology of PTSD in this region. Complimentary DNA (cDNA) is reverse 
transcribed from the collected RNA, and then products of genes of interest are amplified 
during the qPCR reaction using specifically designed primers. The expression level of the 
genes of interest were then compared to the ubiquitously expressed gene 18s for 
normalization calculations. Genetic expression levels in the PTSD, MDD, and DepNOS 
cohorts were then normalized to the expression of non-PTSD controls.  
Results: Of the 54 genes of interest analyzed, two genes, NQO1 and IL-6, exhibited 
significantly decreased and increased levels of expression in comparison to the control 
group, respectively (p < 0.05). Alongside this, NQO1 showed significantly decreased 
expression in comparison to the DepNOS cohort, while IL-6 exhibited significantly 
increased expression in comparison to the MDD cohort (p < 0.05).  
Conclusion: Two genes involved with the production and elimination of reactive oxygen 
species were identified with having significantly altered levels of expression. NQO1, 
which facilitates the removal of ROS was shown to have significantly lower expression 
when compared to the control group, indicating an inhibited ability to remove ROS 
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readily. Furthermore, IL-6, a proinflammatory cytokine and a promotor of ROS 
production, exhibited significantly increased expression, indicating a potential increase in 
ROS formation. Together these results indicate a potential mechanism for the production 
and accumulation of ROS in patients with PTSD, leading to the observed 
neurodegeneration.  
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 1 
INTRODUCTION 
 
History and Development of PTSD  
Throughout history there has been an identified and coupled relationship between 
the experience of stressful events and the development of emotional and psychiatric 
changes, including the report of such syndromes as railroad spike by Dr. Wallace Lewis 
in the mid-nineteenth century and the studies conducted by the French neurologist Jean-
Martin Charcot and his students in the late nineteenth century (Lasiuk et al. 2006). 
Although a number of studies looked at groups of people in stress prone jobs, or civilians 
who survived natural disasters, most of the observations came from civilians and veterans 
who experienced wartime trauma. Such observations date back as far as the field notes of 
Stephen Crane and his accounts of survivors of the Civil War (Andreasen 2010; Lasiuk et 
al. 2006). The current understanding and recognition of PTSD has only come into 
existence in large part due to its high rate of occurrence during times of war and conflict.  
 During World War I (WWI) the first parallel condition was recorded and 
observed by the psychiatrist Charles Samuel Meyers, who developed the term shell shock 
to describe the soldiers who developed a psychological condition brought on by exposure 
to the stresses of war (Andreasen 2010; Crocq et al. 2000). Meyers made sure to 
differentiate this condition from shell concussion, a neurological condition caused by 
blunt force trauma from falling shells. This distinction indicated a distinct difference 
between the development of neurological damage from physical traumas to the head and 
neurological damage caused by psychological trauma. Although the condition was 
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observed heavily during the war and for a time afterwards, it lapsed into the background 
until it was brought back into the forefront during World War II (WWII). Following 
WWII the scientific world became more connected, and information was shared more 
readily between experts. This exchange of information, especially in the medical 
community, brought forth the recognition for the need to establish a set of criteria for 
specific conditions, including psychiatric conditions, resulting in the first edition of the 
Diagnostic and Statistical Manual for the American Psychiatric Association (DSM-1) 
(Andreasen 2010). In this initial edition was the inclusion of gross stress reactions, a 
section detailing stress syndromes that develop in response to extreme stress conditions, 
such as shell shock (Andreasen 2010). While the subsequent edition removed this 
diagnostic section from the manual, mostly attributed to the relative peacefulness of the 
time, it reappeared in the third edition of the DSM, its review and release occurring 
directly after the end of the Vietnam War, with the now current diagnosable condition 
PTSD (Andreasen 2010; Lasiuk et al. 2006). While early descriptions of PTSD, and 
PTSD related disorders, made a note that the diagnosis of such a disorder could only take 
place in an individual with no previous or current psychiatric condition, as the 
understanding of PTSD evolved it has to been reevaluated to recognize that the disorder 
has the tendency to occur alongside other psychiatric conditions, such as anxiety 
disorders and depression (American Psychiatric Association 2013). Thus, like many other 
medical conditions and diseases, the understanding of PTSD has changed over time.  
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Diagnosis Criteria and Prevalence of PTSD 
As currently outlined in DSM-V, PTSD is an anxiety disorder initiated by the 
exposure to a traumatic event that involves intense fear and helplessness, as well as the 
concurrent experience of a serious injury or death to oneself or others (American 
Psychiatric Association 2013). Additional criteria for diagnosis include nightmares, 
flashbacks and remembrances of the trauma, apathy, aggression or risky behavior, and a 
certain duration for the presentation of symptoms (Table 1). 
DSM-V Criteria Operationalization 
Criteria A: 
Exposure to traumatic event 
threatening death or serious injury 
of self or others 
Direct exposure, witnessing of traumatic event, 
learning that event effected close other, 
experiencing repeated exposure to details of 
event  
Criteria B: 
Intrusion, one or more symptom(s) 
required 
Intrusive recollections 
Repetitive play with event-related themes 
Distressing dreams 
Frightening dreams without recognizable 
content 
Flashbacks/recurring of the event 
Trauma-Specific reenactment in play 
Internal/external cues triggering either 
psychological distress or physiological 
reactivity 
Criteria C: 
Avoidance, one or more 
symptom(s) required 
Effortful avoidance of memories, thoughts, 
and/or feelings, about the traumatic event in 
question 
Effortful avoidance of external reminders about 
the traumatic event 
Table 1. Criteria for Diagnosis of PTSD. List of symptoms and requirements for the diagnosis of 
PTSD in clinical patients. (American Psychiatric Association).  
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DSM-V Criteria Operationalization 
Criteria D:  
Negative alterations in cognition 
and mood, two or more symptoms 
required 
Inability to remember aspect of traumatic event 
Persistent negative beliefs about self, others, or 
the world 
Persistent distorted cognitions about cause or 
consequence of the traumatic event, including 
blame of self or others 
Persistent negative emotional state 
Diminished interest in activities 
Feelings of detachment 
Persistent inability to experience positive 
emotions 
Criteria E: 
Alterations in arousal and reactivity, 
two or more symptoms required 
Irritability or outbursts of anger 
Reckless or self-destructive behavior 
Hyper-vigilance  
Exaggerated startle response 
Difficulty in concentration 
Difficulty falling or staying asleep 
Criteria F: 
Duration of disturbance  
Symptoms persist more than one month 
Criteria G:  
Functional Impairment 
Significant distress or impairment in social, 
occupational, or other important areas of 
functioning 
Criteria H: 
Exclusion 
Disturbance not attributable to physiological 
effects of substance or medical condition 
 
Due to the variety of criteria for diagnosis, the clinical presentation of PTSD varies, and 
even the type of traumatic experience that is tied to the disorder and the age at which the 
trauma occurs can result in different behaviors. For example, children who experience 
trauma and develop PTSD have a tendency to exhibit developmental regression, such as 
the loss of language and speech, while those exposed to prolonged traumatic experiences 
might exhibit dissociative symptoms (American Psychiatric Association 2013). With 
increased interest in studying the biological underpinnings of PTSD, a number of risk 
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factors that are tied to the development of PTSD have been identified, including having a 
pre-existing psychiatric condition, such as depression disorders of obsessive-compulsive 
disorder (OCD), and certain genetic and physiological factors, including age of trauma 
exposure, gender, and particular genotypes (American Psychiatric Association 2013). 
While development of PTSD can occur at any point in a person’s lifetime, symptoms for 
PTSD tend to begin presenting themselves around three months after exposure to the 
trauma, and while some cases are resolved within months after presentation of symptoms, 
other cases persist for years or even decades (American Psychiatric Association 2013).  
 Across the general population the prevalence of PTSD hovers at around 3.5%, but 
when age is taken as a factor that statistic more than doubles to 8.7% in individuals 
(Kessler et al., 2005; Vasterling et al. 2016). While traumatic events associated with 
PTSD range from natural disasters, to sexual assault, to work place trauma, especially 
among first responders, the most associated experience with the development of PTSD is 
exposure to wartime trauma. An increasing number of studies and evidence show that 
exposure to war results in upwards of a 25% occurrence of PTSD in veterans returning 
from deployment. This statistic is largely consistent even when taking into account a 
number of variables, including gender, age, combat role, and rank (Vasterling et al. 
2016). This observation is largely consistent across a number of studies, and is not 
limited to individuals in a military or combat position. A study conducted on the 
prevalence of PTSD among adolescents who lived through modern Lebanese conflicts, 
including Operation Grapes of Wrath and the July War, reported a similar statistic among 
civilians exposed to wartime associated traumatic experiences (Shaar 2013). The 
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indication of a prevalent occurrence of the development of PTSD in veterans and 
civilians with wartime exposure brings a sharp focus on the need for a better 
understanding of the biology, pathology, and progression of the development of PTSD 
Physiological Changes and Treatment of PTSD  
 Early treatment for PTSD resolved mainly around behavioral and psychological 
therapies, mainly due to the psychiatric nature of the disorder and no measurable 
physiological changes during the early years PTSD was recognized as a disorder. 
Common therapies used to treat PTSD include exposure therapy, cognitive behavioral 
therapy, and cognitive processing therapy. However, it is now common to utilize 
psychotropic drugs in addition to psychological and behavioral therapies due to a stronger 
understanding of the neurochemistry and brain regions disrupted in PTSD (American 
Psychiatric Association 2013). PTSD is characterized by the long-term remembrance of a 
traumatic experience, changes in the behavior and rational thinking of the patient, and the 
experience of fear and negative emotions associated with the traumatic memory. By 
focusing on the symptoms that PTSD presents for its diagnosis, it becomes clear the 
regions of the brain that are closely tied with the functioning of the disorder, and whose 
function is likely disrupted, including the hippocampus, hypothalamus, prefrontal cortex, 
and the limbic system, that pharmacological agents could be used to stabilize and 
counteract (Pitman et al. 2012). These regions of the brain play important roles in the 
storage and development of memories, cognition, executive functions, emotion 
regulation, and stress response regulation (Figure 1). A number of studies have also 
pointed to physical changes in these regions in patients with PTSD, including thinning of 
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the prefrontal cortex and the hippocampus, while unassociated areas, such as the motor 
cortex, and remain unchanged (O’Donovan et al. 2015; Li et al. 2013; Logue et al. 2013; 
Kaminsky et al. 2015; Liu et al. 2016). These physical changes to areas associated with 
PTSD provide a link between the occurrences of the disorder with quantifiable alterations 
in the in specific regions, indicating specific structural changes as opposed to system 
wide changes. These physical and morphological changes provide a potential foundation 
for identifying potential biological pathways that could also be disrupted in patients with 
PTSD.  
Figure 1. Defective Function of Brain Regions Associated with PTSD. A comparative analysis of the 
functions of brain regions associated with PTSD between the normal function seen in 
individuals without PTSD and the dysfunction seen in individuals with PTSD (Mahan & 
Ressler, 2012). 
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Although pharmacological methods are being used more and more in the treatment of 
PTSD, the biological foundation and sequence of biological events resulting in the 
development of the disorder is still not very well understood, and a number of various 
pathways and systems have been pointed to as potential causes for PTSD.  
The Hypothalamic-Pituitary-Adrenal Axis and PTSD 
One such system approached is the hypothalamic-pituitary-adrenal (HPA) axis. 
One of the hallmarks of PTSD is the occurrence of a state of prolonged and continual 
stress in the patient, resulting in symptoms such as aggression and difficulty sleeping. 
The HPA axis regulates the release of cortisol throughout the body and is the control 
center for regulating stress responses (Figure 2).  
 
  
 
 
 
 
 
 
 
 
 
 
Figure 2. Hypothalamic-Pituitary-Adrenal Axis. Detailed diagram of the HPA axis, including the 
regulation of the axis via the usage of cortisol on glucocorticoid receptors (GRs) (Juruena 
et al., 2004). 
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Alongside cortisol regulation the HPA axis has a number of other functions, including 
immune system activity regulation and the regulation and production of catecholamines, 
particularly epinephrine and norepinephrine, which regulate the fight or flight response 
(Kumar, Abbas, and Aster 2013).  
 Recent studies have provided evidence of the dysregulation of cortisol in 
peripheral fluids, with altered levels of cortisol detected in patients with PTSD (Kellner et 
al. 1997; Wahbeh et al. 2013; Wessa et al. 2006; Yehuda et al. 2005). While cortisol is 
able to easily be measured in a number of different fluids, including urine and saliva, 
studies measuring cortisol levels in PTSD patients have been widely inconsistent. This 
inconsistency is due in part to the intricacies of accurately measuring cortisol, including 
its expression differing at various times throughout the day, with the highest levels being 
detected in the morning. Other variables that influence the level of circulating cortisol 
includes the gender of the subject, the time of collection, and the fluid from which it is 
measured (Wahbeh et al. 2013; Yehuda et al. 2005).  
 Alternatively, other studies focusing on dysregulation of the HPA axis have 
identified the loss of control of catecholamines, and subsequent loss of control of the 
hyperarousal and acute stress response states, as potential areas of interest (Yahyavi et al. 
2015). Catecholamines, specifically epinephrine and norepinephrine, are key components 
of the mammalian acute stress response, resulting in physical changes such as increased 
blood pressure, heart rate, arousal, memory retrieval, attention, and anxiety. The 
activation of many of these physical changes can be seen as being associated with the 
symptoms attributed to PTSD, most noticeably the increased state of arousal and memory 
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retrieval. Cortisol and the HPA axis play an important role in the regulation of the ratio 
levels between norepinephrine and epinephrine. While norepinephrine is produced via 
oxidation of the catecholamine dopamine, epinephrine is a product of norepinephrine 
using the enzyme phenylethanolamine N-methyltransferase (PNMT), which uses cortisol 
as a cofactor for proper function (Kumar et al. 2013). While the exact nature for the 
dysregulation of cortisol is inconclusive, there is a strong consensus for the increase level 
of norepinephrine in patients with PTSD. The increased expression of norepinephrine is 
of interest due to its role in the sympathetic nervous system and its role in maintaining a 
state of increased stress. Also, unlike epinephrine, which is produced primarily in the 
adrenal cortex, norepinephrine is produced and stored in neurons and has a stimulatory 
effect, causing an increase in heart rate, blood flow, and an increase in the release of 
glucose. While normal expression of norepinephrine plays a key role in regulating the 
stress response, dysregulation of the expression of norepinephrine has been linked to 
hyperarousal and increased memory retrieval (Wilson et al. 2014; Wingenfeld et al. 
2015). It could be viewed that in the case of a decrease in the expression of cortisol it 
would result in the potential for the accumulation of norepinephrine because it could no 
longer be converted into epinephrine. However, the function and regulation of the HPA 
axis is not so simple and clear cut.  
The Glucocorticoid Pathway and PTSD 
 While a major function of cortisol is the regulation and production of particular 
catecholamines, another role of cortisol that is of interest is the function of cortisol as a 
glucocorticoid and its activation of the glucocorticoid receptor (GR) pathway. Cortisol, 
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and other glucocorticoids, have a conserved steroidal structure and help regulate, among 
other things, glucose metabolism. Due to their conserved structure, cortisol and other 
glucocorticoids are able to cross the cell membrane and bind to cytoplasmic 
glucocorticoid receptors, which are found throughout the body, and then proceed to 
activate and regulate a number of biological processes (Daskalakis et al. 2013). After the 
receptor is translocated into the nucleus it is able to bind to specific DNA regions and 
activate or suppress different transcription factors. The GR pathway has become of 
interest for a number of reasons in the study of PTSD. Evidence has pointed to the 
atrophic effect of glucocorticoids on the central nervous system, especially in the 
hippocampus where there is a large density of glucocorticoid receptors in the tissue 
(Sapolsky 2000).  
A number of studies have initially looked at the genes that regulate the receptor’s 
sensitivity to cortisol and other glucocorticoids and the gene that encodes the receptor, 
FKBP5 and NR3C1 respectively, to determine if there is a link between the dysregulation 
of the HPA axis and the GR pathway. There is evidence of epigenetic changes to FKBP5, 
the gene that regulates the sensitivity of the receptor, as well as being important for 
neuron growth and plasticity, resulting in the suppression of its expression due to 
hypermethylation (Yehuda et al. 2016; Muhie et al. 2015). As FKBP5 works as part of 
the inhibitory complex that sequesters the glucocorticoid receptor, methylation of the 
gene would result in an increase in the sensitivity of the receptor of glucocorticoids, with 
more receptors being unbound in the cytoplasm. This increase in sensitivity would 
increase the resulting downstream alterations in the GR pathway. Simultaneously, 
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evidence points to dysregulation in the expression of the receptor gene NR3C1 as well, 
specifically hypomethylation of the gene resulting in an increase expression and 
production of the receptor (Muhie et al. 2015; Yehuda et al. 2015). This paired 
occurrence of increased expression of the NR3C1 gene and lower expression of the 
FKBP5 gene points to the potential for an overstimulated GR pathway, and the possibility 
for downstream targets to be over expressed. Of equal significance, however, is the 
potential link between the methylation and expression of the receptor gene and the risk 
for the development of PTSD. A study conducted on the survivors of genocide indicated 
that individuals with increased methylation of the NR3C1 gene had a decreased risk of 
PTSD (Vukojevic et al. 2014). Tying this back into the toxic effects of glucocorticoids, if 
there is an increase in the density of glucocorticoid receptors, due to the over expression 
of the receptor gene, in other regions of the brain outside of the hippocampus associated 
with PTSD, but not others, this could result in the occurrence of specific sites of atrophy 
in the disorder. It has been argued that this shift towards a hypersensitive state is a result 
of the dysregulated HPA axis, particularly in response to decreased cortisol levels 
(Daskalakis et al. 2013). More so, this also indicates that individuals who have a higher 
level of methylation of the NR3C1 gene potentially are shielded from the risk for 
developing PTSD through this mechanism. This does, however, bring into question the 
temporal status of the genetic modifications of the GR pathway, and whether these 
different levels of methylation and expression are a result of the development of PTSD or 
pre-existing risk factors, and how these two components influence one another. While on 
the surface the dysregulation of GR pathway might appear clear cut in PTSD, it is in fact 
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a complex system with a number of checks and balances, and a number of studies have 
looked at downstream regulators of the GR pathway. A study on the methylation of 
SKA2, a chaperon protein that assists in the transport of the receptor from the cytoplasm 
into the nucleus, has been shown to be hyper-methylated, indicating that while the 
expression and sensitivity of the receptor might be increased, a number of its downstream 
components might potentially be inhibited (Sadeh et al. 2016).  
 One reason that the GR pathway is of such interest in the study of PTSD is due to 
the variety of systems and pathway it influences (Figure 3).  
 
Figure 3. Functions and Effects of Glucocorticoids. A collection of the diverse functions of 
glucocorticoids, including their influence on the immune system and apoptosis (Baschant 
et al., 2012). 
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One example of a gene that the GR pathway regulates is the expression of the CREB 
gene, which has been linked to the formation of long-term memories and neuronal 
plasticity (Lee et al. 2009; Zou et al. 2006).  Through the regulation of the CREB gene, 
the GR pathway is able to influence the success of the retention and formation of long-
term memories, potentially providing a mechanism for the development of the retention 
of traumatic experiences and the triggers associated with the event. Another system that 
is influenced by the GR pathway is the cell cycle and programed cell death, through the 
regulation of the expression of CEBP genes, and STAT5, OCT1, and OCT2 (Kang et al. 
2009; Sebastian et al. 2009). Disruption of the cell cycle and abnormal activation of 
apoptosis could contribute to a number of the pathologies associated with PTSD, 
including brain structure volume loss and neuronal damage.  
The Immune System, Inflammation, and PTSD 
 A final area that is regulated by the GR pathway is the immune system, especially 
the production of cytokines and activation of the inflammatory process (Castro-Vale et al. 
2016). The inflammatory process is a tightly controlled system, and dysregulation of the 
system can result in continual tissue damage, either by the continuation of the stimuli or 
due to hyperactivity of the inflammatory response. There are two classifications of 
inflammation, either acute inflammation or chronic inflammation, and the classifications 
are characterized both by the biological responses, as well as the cells and proteins 
involved in the response, and the duration of the response since the initiation of the 
inflammatory process. Acute inflammation is initiated shortly after the introduction of the 
harmful stimuli and is characterized by increased vascular permeability and the 
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translocation of leukocytes into the damaged tissue. Chronic inflammation occurs when 
there is a state of prolonged inflammation, and it is characterized by the utilization of 
mononuclear cells and the progressive destruction and restoration of the inflamed tissues. 
Chronic inflammation is mitigated primarily through macrophage activation and their 
resulting downstream affects, including the production of reactive oxygen species (ROS), 
nitric oxides (NO), lysosomal enzymes, and chemokines, and the process is regulated by 
a number of cytokines, including IFN-ɣ, IL-4, and IL-13 (Andrews et al. 2012). Of the 
various immunological components of inflammation, macrophages are of particular 
interest for a number of reasons. The central nervous system is a vital component of 
human biology and it is strongly protected by a number of mechanisms, including the 
blood-brain barrier. The blood-brain barrier plays an important role, not only in 
protecting the central nervous system from infectious agents and toxins, but also in 
preventing the infiltration of accumulation of circulating lymphocytes and other immune 
system cells and cytokines (Shetty et al. 2014). While the central nervous system is 
protected from peripheral immune system components, it also contains innate 
immunological components to fight off infections, most notably microglia cells. 
Microglia cells are central nervous system specific macrophages that reside throughout 
the central nervous system, and as such provides immune system protection within an 
enclosed space without the need to allow for the penetration of the blood-brain barrier 
(Bollinger et al. 2016). Macrophages are also of interest due to their function in chronic 
inflammation. While lymphocytes play a fast paced role in the acute inflammatory 
response and then quickly die off, macrophages are slow in their activation and, due to 
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their longer cellular lifespan and ability to recruit and activate other macrophages using 
specific cytokines, play a key role in the propagation and continuation of inflammation 
(Kumar et al. 2013). These functions are of interest in the study of PTSD due to the long 
latency period of the disorder and the tissue specific pathological changes seen in the 
central nervous system tissue. Due to the slow initiation and long duration of chronic 
inflammation, and the presence of a tissue specific macrophage held throughout the 
central nervous system, the dysregulation of macrophage activity and chronic 
inflammation has been identified as a potential feature of PTSD. Macrophages are also of 
interest due to their functional regulation by specific cytokine signaling. Macrophages 
have two distinct functions, and, as a result, can be divided into two separate categories 
based on those functions (Martinez et al. 2014) (Figure 4). 
 
Figure 4. Activation and Function of M1 and M2 Macrophages. A model indicating the pathway for 
the polarization of macrophages and the cytokines and components that regulate the 
differentiation (Canton et al., 2013). 
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 The first category is M1 macrophages, whose production and stimulation is 
regulated by the expression of IFN-ɣ and foreign microbes, and the production of M1 
macrophages is inhibited by the expression of IL-4 and IL-13. M1 macrophages are the 
offensive front of the macrophage response; they kill and eliminate foreign microbes and 
bacteria through the production of ROS, NO, and lysosomal enzymes, and initiate the 
process of chronic inflammation through the production of particular cytokines (Martinez 
et al. 2014). M2 macrophages are regulated by the reciprocal of the M1 macrophage 
system, and as such are stimulated into production through the expression of IL-4 and IL-
13, and are inhibited by the expression of IFN- ɣ and foreign bodies. M2 macrophages, as 
opposed to M1 macrophages, play an important role in the induction of tissue repair and 
the initiation of fibrosis and the anti-inflammatory response (Martinez and Gordon 2014). 
Due to this system of opposing functions through a single cell type, there is a set timeline 
from the initiation of the cytotoxic and inflammatory activity of M1 macrophages and the 
transition to the tissue repair and anti-inflammatory activity of M2 macrophages. 
Outside of the more linear cytokine signaling cascades that regulate immune 
system responses, there are other peripheral mediators that influence the natural 
progression of immune and inflammatory responses. One such example of this is cortisol, 
a steroid that has exhibited anti-inflammatory and immunosuppressant capabilities 
(Yahyavi et al. 2015). Cortisol has been shown to suppress and hinder immune responses, 
including inflammation, by inhibiting the production of a number of cytokines.  In the 
case of PTSD, where there is prolonged stress and impaired immune function, it is 
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possible that the natural process of chronic inflammation becomes disrupted and proceeds 
unchecked.  
 Due to the intersectional relationship between the stress response system and the 
inflammatory response, components of the chronic inflammatory response have been 
identified as potential areas of focus. Studies conducted on the expression of specific 
cytokines in the peripheral mononuclear cells in patients with PTSD found that the 
expression of a number of specific cytokines, including IFN- ɣ and IL-12, were elevated 
when compared to non-PTSD veterans (Bam et al. 2016). Other studies have focused on 
the expression of various cytokines, and a number of them have been noted to be 
irregularly expressed as well, including IL-1, IL-6, IL-8, and TNF-⍺ (Gardiner et al. 2013; 
Lindqvist et al. 2014; Neylan et al. 2011). IFN- ɣ is a key component in the activation of 
the M1 macrophages during immune and inflammatory responses, and abnormal IFN- ɣ 
expression has been associated with a number of autoimmune diseases (Hoge et al. 
2009). IFN- ɣ is expressed by a number of different cells, including natural killer cells, 
lymphocytes, including both CD4 helper and CD8 cytotoxic T-cells, and macrophages, 
making the cytokine involved in both innate and adaptive immunity. IFN- ɣ has two 
stimulatory effects of note in regards to PTSD, the activation of M1 macrophages, and 
the activation of the inducible nitric oxide synthase, which increases the production of the 
oxidative stress agent nitric oxide (Hoge et al. 2009). While IFN- ɣ is used to activate 
macrophages, it can also be produced by microglia, potential resulting in the creating of a 
self-sustaining loop of the activation of macrophages and the expression of IFN- ɣ. IFN- 
ɣ also inhibits the activation of M2 macrophages, resulting in the suppression of the 
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tissue repair, fibrosis, and anti-inflammatory functions of macrophages (Hoge et al. 
2009). IL-12 is another cytokine of interest for two main reasons. IL-12 is a cytokine that 
plays a role in initiating and continuing the inflammatory state, and it has been found to 
be up-regulated in peripheral mononuclear cells, indicating a likelihood of its increased 
expression in microglia cells (Bam et al. 2016; Gola et al. 2013). As IL-12 is a cytokine 
that stimulates and promotes the inflammatory response, its over-expression could result 
in the formation of a continuous chronic inflammatory state. IL-12 is also capable of 
regulating and promoting the expression of IFN- ɣ via the activation of the Jak-STAT 
pathway (Bam et al. 2016). By increasing the expression of IFN- ɣ, IL-12 can stimulate 
the production of M1 macrophages, and, in turn, promote the expression of ROS, NO, 
and inflammatory cytokines. IL-1 is an interleukin that similarly promotes the 
progression of the inflammatory state, and its expression has been shown to be increased 
in patients with PTSD (Spivak et al. 1997). Parallel to IL-12, IL-1 is released by M1 
macrophages, and it could be a driving force behind sustained chronic inflammation in 
the presence of a dysregulated inflammatory state (Spivak et al. 1997). As opposed to IL-
1 and IL-12, IL-6 and IL-8, while still involved in the inflammatory response, play more 
of a role in acute inflammation. IL-6 is an important regulator of the acute inflammatory 
response, but it also plays a role in anti-inflammatory functions and activates the 
expression of prostaglandin E2 in the hypothalamus (Scheller et al. 2011). IL-8 also plays 
a significant role in the acute inflammatory process, primarily in the recruitment and 
activation of neutrophils (Harada et al. 1994). A final cytokine of note is TNF-⍺. TNF-⍺ 
is a cytokine involved in the inflammatory process, and, like IFN- ɣ, one of its main 
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function is the regulation of immune cells, especially in the production of the IL-1 and IL-
6 expressing macrophages. Dysregulation of TNF-⍺ has been found to be present in 
individuals with Alzheimer’s disease and depression, common co-morbidities with PTSD 
(Nowotny et al. 2010). Through binding to the TNF receptor, TNF-⍺ is able to stimulate 
a number of downstream affects, mostly through the activation of other transcription 
factors, including NF-ĸB and AP-1, both of which influence the production of cytokines 
and the regulation of the stress response (Nowotny et al. 2010; Bland et al. 2005). 
Another factor to note about the transcription factors regulated by TNF-⍺ is the 
commonality between them and the transcription factors activated by the GR pathway. 
While the GR pathway does not regulate TNF-⍺ expression, both the GR and the TNF-⍺ 
receptor regulate NF-ĸB expression, and the GR regulates c-Fos and c-Jun expression, 
both of which are components of the AP-1 transcription factor complex (Nowotny et al. 
2010; Bland et al. 2005). Another factor that is produced in a chronic inflammatory state 
is the production of oxidative agents, including ROS and NO, and the potential for the 
production of a state of oxidative stress.  
Oxidative Stress and its Role in PTSD 
Oxidative stress is a state where the production of oxidative agents outpaces the natural 
removal of these agents through anti-oxidant pathways. Oxidative agents are naturally 
produced throughout the body either as a defense mechanism by immune cells to combat 
foreign invaders, or as a by-product of oxidative phosphorylation and glycolysis (Figure 
5). The production of oxidative agents via glycolysis and oxidative phosphorylation is of 
particular interest in the study of PTSD for a number of reasons. First, as opposed to 
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other tissues, the brain only uses glucose, and as such glycolysis and oxidative 
phosphorylation, as a source for ATP production, and this ATP production increases 
during the waking state. Tied to this, one of the symptoms of PTSD is night terrors and 
disruption of the natural sleep cycle (American Psychiatric Association 2013). This 
would imply that in patients with PTSD, there is an increase in the breakdown and 
utilization of glucose in the brain for energy due to the increased duration of the wakeful 
state. In fact, it has been shown that in PTSD patients there is an increase in glucose  
Figure 5. In Vivo Formation of Reactive Oxygen Species. A diagram detailing the endogenous 
creation and formation of reactive oxygen species within cells (Jackson et al., 2007). 
metabolism in brain regions associated with the disorder, including the amygdala 
(Ramage et al. 2016). Similarly, it has been shown that during acute and chronic states of 
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stress there is an increase in glucose availability (Torres et al. 2001). This increase in 
glucose availability would allow for the potential for the increased utilization of glucose 
as needed. While glucose is generally transported across the blood-brain barrier into the 
central nervous system when required, there are energy stores of glycogen held in 
astrocytes (Rosenberger et al. 2001). Astrocytes play a number of roles in the central 
nervous system, including the storage of glucose for adjacent neurons, structural support 
of the blood-brain barrier, and the uptake and release of neurotransmitters. However, 
while astrocytes are capable of a number of different functions, these functions are not 
universal across all astrocytes. It has been shown that astrocytes coupled to neurons in the 
frontal cortex and the hippocampus assist in the formation of long-term memory 
formation through the utilization of lactate (Steinman et al. 2016). This would indicate 
that there might be an important role in the function of astrocytes for the development 
and continuation for PTSD. Energy production is not the only endogenous source of 
oxidative agents. As discussed earlier, oxidative agents, such as ROS and NO, are 
produced during normal immune system activity in order to combat invasive pathogens. 
NO is also endogenously expressed by endothelial cells to regulate blood flow, as well as 
produced by neurons to regulate the release of neurotransmitters. Oxidative agents are 
capable of causing cellular and tissue wide damage in a number of different ways, 
including lipid peroxidation and by inducing genetic mutations (Borovac Stefanovic et al. 
2015) (Figure 6). ROS and NO are damaging and harmful to cells and tissues due to their 
chemical structure and reactivity. Oxidative agents are free radicals, and as such they 
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contain a free outer electron that readily reacts with both organic and inorganic 
substances, mainly by attacking double bonds.  
In the case of lipid peroxidation, a reaction that results in the destabilization of the 
lipid structure, the free radical removes a vulnerable hydrogen, resulting in the formation 
of a free electron on the lipid chain that attempts to stabilize itself by acquiring hydrogens 
from surrounding lipids (Borovac Stefanovic et al. 2015). In this way, the process of  
Figure 6. Consequences of Progressive Oxidative Stress. A descriptive outline of the downstream 
consequences of progressive and unregulated oxidative stress in biological systems 
(Dröge, 2002). 
peroxidation, once initiated, is self-propagating and causes the cellular membrane to be in 
a state of unstable fluctuation. The occurrence of oxidative stress also has the potential to 
initiate genetic changes, either through the activation of transcription factors or by 
genetic mutation. During the events of oxidative stress, a process that occurs naturally in 
the body, the imbalance of free radicals triggers the expression of transcription factors 
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that regulate the inflammatory process, such as NF-ĸB, in the attempt to better combat 
the oxidative state and to prevent lasting damage. However, during the occurrence of 
oxidative stress there is a potential for the development of unregulated genetic mutations 
to occur as well, either through the process of base pair modification, cross-linking 
events, or during DNA strand break repair (Borovac Stefanovic et al. 2015). Certain 
oxidative base pairs, guanine in particular, are used as hallmarks for identifying oxidative 
stress due to how readily the oxidation of guanine occurs during oxidative stress 
(Kawanishi et al. 2001; Salmon et al., 2004). If uncorrected by repair enzymes, oxidized 
guanine can result in a base pair transversion from a G-C pair to a T-A pair (Kawanishi et 
al. 2001; Salmon et al., 2004). While these changes occur during oxidative stress, a 
number of more specific changes have been noted to occur in the central nervous system. 
Prolonged oxidative stress in the central nervous system has been linked to the increased 
permeability of the blood-brain barrier, dysregulation of neurogenesis, neurotransmission 
disruption, and changes to neural morphology (Miller et al. 2014; Shetty et al. 2014). 
Oxidative agents don’t just naturally decompose in the body, however, their removal 
depends on an anti-oxidant system. The anti-oxidant system works primarily through the 
reduction of the oxidative species through the addition of hydrogen atoms. These anti-
oxidant enzymes occur naturally through the body, and cluster in cell compartments 
where the production of oxidative agents is naturally high, such as the mitochondria. For 
the most part, anti-oxidant enzymes work primarily on specific oxidative species, such as 
superoxide dismutase (SOD) reducing superoxides produced in the cytoplasm and 
mitochondria in to hydrogen peroxide. Hydrogen peroxide, a ROS, can itself be further 
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reduced into water through the function of glutathione peroxidase and catalase enzymes 
(Rolseth et al. 2008). Other anti-oxidant enzymes, such as Glyoxalase 1, require specific 
cofactors to function, such as the microglia produced glutathione. In this way it can be 
seen that, in order for oxidative stress to become dysregulated and the accumulation of 
oxidative agents to summate out of control, very few changes need to occur. 
Genetic Diversity and Dysfunction Seen in PTSD  
 Due to the variety, yet interconnectedness, of the systems involved in the 
pathology and development of PTSD a shift towards better understanding and identifying 
the genetic changes associated with the disorder has become a point of interest. One of 
the major reasons that genetic studies have become of interest is due to their scope. As 
opposed to studies on physiological changes, such as cortisol production, genetic studies 
can easily identify changes through an entire system due to the increased number of 
targets that could be measured, potentially leading to a clearer understanding of the 
changes that occur. This type of detailed inquiry is particularly useful in systems like the 
GR pathway, where there are a number of components in the pathway affecting various 
physiological systems, as well as a number of peripheral factors that regulate the activity 
of the pathway. Other reasons for the shift towards genetic studies include its relative 
ease, replicability, and expedience. These characteristics of genetic studies allow for 
diverse inquiries into biological systems and pathways. Alongside this, genetic studies 
also provide the potential to study patients over the course of the life of a patient, and 
even post-mortem, allowing to track and catalog changes in genetic expression over the 
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development of the disorder, and even compare the changes across a large cohort to 
identify unique and conserved genetic alterations.  
 The focus on genetics in PTSD has branched mainly in two different directions, 
looking at polymorphisms and epigenetic changes that result in altered expression levels 
of particular genes of interest.  
 A polymorphism is the occurrence of genetic variation within a set population that 
results in differences in the function or expression of the altered gene. Polymorphisms 
can occur and present themselves in a number of different ways, but the most common 
form of genetic polymorphism are single nucleotide polymorphisms (SNPs). SNPs can 
result from the introduction of a mutagen or due to errors in replication or DNA repair, 
such as the repair process activated during oxidative stress induced DNA damage 
(Maddox et al. 2013). Various studies have looked into polymorphisms found in 
particular genes, such as FKBP5 and NR3C1, to elucidate the relationship between the 
function of particular genes and the occurrence of PTSD (Yehuda et al. 2016; Yehuda et 
al. 2015; Vukojevic et al. 2014). These polymorphism studies are of unique interest to the 
study and treatment of PTSD because, as opposed to mutations or epigenetic changes, 
polymorphisms are conserved genetic variation present within a population, and as such 
could help identify individuals with an increased risk to develop diseases or disorders.  
 The second direction that is a focus for genetic studies of PTSD is epigenetic 
studies. As opposed to polymorphisms, which are conserved genetic changes in a subset 
of a population, epigenetic changes can occur throughout an individual’s lifetime as a 
result of physiological changes, such as a continuous state of oxidative stress, nutritional 
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suppression, or mutagen exposure (Gu et al. 2013). Unlike polymorphisms or other 
mutations, which are changes found within the DNA sequence, changes of the epigenome 
result in alterations to the non-sequence structure of DNA creating differences in the 
transcription of the genome (Gu et al. 2013). Like polymorphisms, however, epigenetic 
changes can result in either the increase of decrease expression of particular genes 
depending on the changes that take place, either through the level of methylation on the 
promoter region of the gene or through the level of acetylation of the histone proteins 
DNA is packaged around. Gene silencing through methylation occurs through the 
addition of methyl groups onto the CpG islands upstream of the transcription start site 
(Maddox et al. 2013). Gene activation can also be accomplished in the reverse process, 
through the removal of methyl groups from CpG islands. Alongside the utilization of 
methylation as a regulation for gene transcription, DNA methylation has been association 
with chronological age and loss neural integrity, especially in regions that deteriorate 
with increasing age, such as the prefrontal cortex (Wolf et al. 2016). A variety of studies 
have also shown that exposure to chronic stress, trauma, and oxidative stress can result in 
accelerated DNA methylation (Wolf et al. 2016; Čeprnja et al. 2011). Furthermore, 
genome-wide studies on methylation levels indicate that methylation changes might not 
be random, but instead fairly specific. A study conducted by Smith and colleagues 
indicated that, alongside the increased methylation of certain genes of interest associated 
with PTSD, the overall level of DNA methylation was also significantly different (Smith 
et al. 2011). These results would indicate that methylation changes as a result of the 
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development of PTSD are associated with the observed physiological changes in the 
patients, as well as other global changes. 
 Histone acetylation, however, influences gene expression in a different way. In its 
larger organization DNA is compressed and wrapped around histone protein complexes 
in order to fit in the limited space of the nucleus. DNA packaging around histone proteins 
is primarily a result of the difference in the charges between the histone proteins and 
DNA. When the negatively charged DNA is tightly wrapped around the positively 
charged histone proteins, the transcription proteins are not capable of interacting with and 
binding to the genome. However, when acetyl groups are added to vulnerable lysine 
amino acids via the Histone Acetyl Transferase (HAT) enzymes, the histone complex 
becomes more neutrally charged and DNA becomes less tightly bound. This allows for 
previously non-transcribable genes to become available for transcription. Deacetylation, 
and suppression of gene transcription is also possible through the reverse process using 
Histone Deacetylase (HDAC) enzymes (Maddox et al. 2013).  
 With the shift towards viewing oxidative stress as a defining characteristic of 
PTSD, there has also been a corresponding shift towards mitochondrial DNA (mtDNA) 
and potential structural and mutagenic changes that it acquires. There a number of 
characteristics unique to mtDNA, including the limited number of genes, the fact it is 
inherited singularly from the maternal source, and, of particular interest, its proximity and 
potential interaction with ROS produced as by-products from oxidative phosphorylation 
(Alexeyev 2009). Although it is debated whether the proximity between the produced 
ROS increases the risk for mtDNA to develop mutations, it has been noted that a number 
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of age-related diseases associated with acquired mtDNA damage (Alexeyev 2009). 
Furthermore, a number of studies conducted on PTSD cases independently identified 
dysregulation of in mtDNA genes, including in the regulation of oxidative 
phosphorylation, production of transfer RNA (tRNA), and RNA subunits (Su et al. 2008; 
and Zhang et al.).  
Of particular interest are the epigenetic changes identified in the GR pathway, 
including the decreased methylation of the glucocorticoid receptor gene and the increased 
methylation of the glucocorticoid receptor sensitive gene (Sapolsky 2000; Yehuda et al. 
2016; Muhie et al. 2015; Yehuda et al. 2015). Other genetic and epigenetic studies have 
focused on the downstream regulators of the GR pathway, including genes that regulate 
the transport of the receptor into the nucleus (Sadeh et al. 2016). Other studies have 
attempted to identify early changes in the development of PTSD in order to try and better 
understand the progression and development of the disorder, particularly studies looking 
at the changes of expression in inflammatory response regulation and cytokine genes. 
Studies have also indicated a relationship between oxidative stress and the abnormal 
expression of particular genes. Many of the studies conducted identified changes in 
expression of genes associated with the regulation of inflammation in reaction to 
increasing levels of ROS (Wilson et al. 2013; Acosta et al. 2013). Genetic studies have 
even begun to try and identify how differences in the initial trauma, age, or gender could 
affect the development of PTSD (Ramo-Fernández et al. 2015). This shift in focus 
towards genetic studies has pointed towards a deeper understanding in the development, 
progression, and dysregulation that occurs in PTSD. As evidence is collected, the 
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consensus appears to indicate that it is not a simple case of a single change resulting in a 
number of downstream changes, but instead a series of changes that result in a mass 
amount of changes in a few select systems.  
 In this study we attempt to provide further insight into the functional expression 
of 54 different genes in the prefrontal cortex of patients with PTSD. The 54 genes chosen 
are involved in a number of pathways and systems, including the function and structure 
of astrocytes, microglia, and neurons, the inflammatory response system, the oxidative 
stress response system, and the blood-brain barrier. While a number of these systems and 
genes have been tested in patients with PTSD, or a PTSD comorbidity, many have not. 
This study focuses on both the potential differences in the expression of these genes in 
the prefrontal cortex and the motor cortex, but also in the differences in the expression 
between patients in the attempt to identify conserved genetic changes associated with the 
development of PTSD.  
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SPECIFIC AIMS 
 Studies focusing on the physiological dysfunction of PTSD have fallen short in 
the attempt to identify and describe conserved genetic changes. In addition, various 
studies have even been shown to have contradictory results in terms of genetic expression 
of particular genes, most notably inflammatory response genes. In this way, while some 
studies might identify a particular gene or set of genes as being differentially expressed in 
individuals with PTSD, a separately conducted study might present contradictory results. 
 This study attempts to compare the genetic expression of a set of genes, either 
tested previously in other studies or as new potential targets, in PTSD patients and non-
PTSD patients. Additional, this study compares the genetic expression of the PTSD group 
with commonly diagnosed comorbidities, namely MDD and DepNOS, in an attempt to 
identify differences in these groups, as well as comparing the expression of the genes of 
interest between PTSD patients, so as to try and identify conserved genetic changes.  
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METHODS  
Subject Recruitment and Assessment  
Sample cases were enrolled into the study through postmortem donation, 
following appropriate protocols. Consent for donation and study was received prior to 
sample collection. Postmortem cases underwent retrospective medical assessment 
utilizing subject medical history, obtained through interviews and available medical 
records. Samples then underwent an assessment protocol in order to provide a 
standardized process for reviewing medical history and records to validate psychiatric 
and medical diagnosis. This provided a standardized process for identifying and 
categorizing subjects with and without lifetime PTSD. Controls were collected based on 
subjects who exhibited no clinical history of neurological disease, and consent was 
obtained at the time of passing from the next of kin. All PTSD, MDD, and DepNOS 
subjects were screened and diagnosed following the guidelines described in the DSM-V 
(American Psychiatric Association 2013) by certified professionals. Medical history was 
collected for subjects, including age of death, cause of death, race, and neurological 
disease status (Table 2).  
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Table 2. Subject Information. Detailed information regarding the biographical information of study subjects.  
 
Subject 
number 
Age of 
Death 
(in 
years) Sex Race 
Postmortem 
Interval (in 
hours) 
Primary 
Diagnosis Final Diagnosis Manner Of Death Cause of Death 
1 48 M CAUCASIAN  45 Control 
No Diagnosis on Axis 
1;Deferred;Obesity;Other (Specify); Natural 
Complications of 
Morbid Obesity 
2 40 M 
AFRICAN 
AMERICAN 26.5 PTSD 
PTSD;Alcohol Dependence;Alcohol 
Intoxication;Deferred;Juraj DB 
Tentative Dx;Hypertension;Other 
(Specify);Seizures; unspecified;Fatty 
liver;Cardiomyopathy; 
unspecified;Congestive Heart Failure 
(CHF); Natural 
Hypertensive 
Cardiomyopathy 
3 50 M CAUCASIAN 26 MDD 
MDD; Single;Alcohol Abuse;Alcohol 
Intoxication;Polysubstance 
Abuse;Deferred;Juraj DB Tentative 
Dx;Hypertension;Other (Specify); Suicide 
Intraoral Gunshot 
Wound 
4 38 M CAUCASIAN 34.5 MDD 
MDD; Recurrent; without 
Psychotic;Alcohol 
Dependence;Alcohol 
Intoxication;Polysubstance 
Abuse;Polysubstance 
Intoxication;Deferred;Juraj DB 
Tentative Dx;Hemorrhage(s); 
subarachnoid;Hypertension;Other 
(Specify);Seizures; 
unspecified;Chronic Pain;Arthritis; 
unspecified; Accident 
Alcohol and 
Chlordiazepoxide 
Intoxication 
5 47 M 
AFRICAN 
AMERICAN 29 PTSD 
Depressive Disorder 
NOS;PTSD;Deferred;Juraj DB 
Tentative Dx;Other 
(Specify);Migraine 
Headaches;Chronic Pain; Accident Multiple Injuries 
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4 
6 44 M CAUCASIAN 34.5 PTSD 
MDD; Recurrent; with 
Psychotic;PTSD;Alcohol 
Dependence;Polysubstance 
Abuse;Polysubstance 
Intoxication;Deferred;Hypertension;
Hepatitis; drug or alcohol 
related;Other (Specify);Fatty liver;  Undetermined 
Fentanyl and 
Chlordiazepoxide 
Intoxication 
7 54 M CAUCASIAN 40 MDD 
MDD; Recurrent; with 
Psychotic;Alcohol 
Dependence;Alcohol 
Intoxication;Deferred;Juraj DB 
Tentative 
Dx;Hypertension;Obesity;Cirrhosis; 
alcoholic;Other (Specify);Seizures; 
unspecified;Atherosclerotic CVD 
(ASHCVD); Natural 
Hypertensive 
Atherosclerotic 
Cardiovascular 
Disease 
8 49 M CAUCASIAN 27.5 DepNOS 
Depressive Disorder NOS;Alcohol 
Dependence;Deferred;Juraj DB 
Tentative Dx;Other (Specify);Chronic 
Pain;Atherosclerotic CVD 
(ASHCVD);Arthritis; unspecified; Natural 
Hypertensive 
Cardiovascular 
Disease 
9 35 F CAUCASIAN 34 MDD 
MDD; Recurrent; with 
Psychotic;Alcohol 
Abuse;Polysubstance 
Intoxication;Deferred;Juraj DB 
Tentative Dx;Pneumonia; 
unspecified;Seizures; 
unspecified;Chronic 
Pain;Atherosclerotic CVD 
(ASHCVD); Natural Pneumonia 
10 36 M CAUCASIAN 38 DepNOS 
Depressive Disorder NOS;Opioid 
Intoxication;Polysubstance 
Abuse;Deferred;Other 
(Specify);Seizures; 
unspecified;Chronic Pain;Arthritis; 
unspecified; Suicide 
Contact Shotgun 
Wound of Chest 
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11 39 F CAUCASIAN 35.5 PTSD 
MDD; Recurrent; with 
Psychotic;PTSD;Phencyclidine 
Abuse;Polysubstance 
Abuse;Deferred;Juraj DB Tentative 
Dx;Chronic Pulmonary Disease 
(COPD);Hypertension;Other 
(Specify);Chronic 
Pain;Atherosclerotic CVD 
(ASHCVD);Diabetes Mellitus; Type 
II (Non-IDDM);Arthritis; 
unspecified; Natural 
Hypertensive 
Cardiovascular 
Disease 
12 50 M CAUCASIAN 28 PTSD 
Depressive Disorder NOS;Panic w/o 
Agoraphobia;PTSD;Opioid 
Intoxication;Polysubstance 
Abuse;Polysubstance 
Intoxication;Psychosis 
NOS;Deferred;Juraj DB Tentative 
Dx;Hypertension;Asthma; 
unspecified;Obesity;Hearing 
loss;Other (Specify); Undetermined 
Fentanyl 
Intoxication and 
Cocaine Use 
13 32 M CAUCASIAN 19 MDD 
MDD; Recurrent; without 
Psychotic;Opioid 
Intoxication;Polysubstance 
Dependence;Polysubstance 
Intoxication;Deferred;Juraj DB 
Tentative Dx;Other (Specify);Chronic 
Pain;Atherosclerotic CVD 
(ASHCVD); Undetermined 
Narcotic (Heroin) 
Intoxication 
14 52 M CAUCASIAN 38.5 Control 
No Diagnosis on Axis 
1;Deferred;Juraj DB Tentative 
Dx;None; Accident Asphyxia 
15 34 M 
AFRICAN 
AMERICAN 30 PTSD 
MDD; Recurrent; without 
Psychotic;PTSD;Alcohol 
Dependence;Alcohol 
Intoxication;Opioid 
Intoxication;Polysubstance Undetermined 
Alcohol and 
Heroin 
Intoxication 
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Abuse;Deferred;Juraj DB Tentative 
Dx;Hypertension;Seizures; 
childhood;Seizures; 
unspecified;Migraine Headaches; 
16 49 F CAUCASIAN 25.5 DepNOS 
Depressive Disorder 
NOS;Polysubstance 
Dependence;Polysubstance 
Intoxication;Deferred;Hypertension;
Other (Specify);Chronic Pain; Suicide 
Verapamil 
Intoxication 
17 40 M CAUCASIAN 15.5 MDD 
MDD; Recurrent; without 
Psychotic;Alcohol 
Dependence;Alcohol 
Intoxication;Opioid 
Dependence;Opioid 
Intoxication;Deferred;Juraj DB 
Tentative 
Dx;Hypertension;Pancreatitis; 
unspecified;Other 
(Specify);Atherosclerotic CVD 
(ASHCVD);Emphysema; Undetermined 
Alcohol and 
Narcotic (Free 
Morphine) 
Intoxication 
18 47 M CAUCASIAN 28.5 MDD 
MDD; Recurrent; without 
Psychotic;ADHD; 
Inattentive;Polysubstance 
Dependence;Polysubstance 
Intoxication;Deferred;Juraj DB 
Tentative Dx;Hypertension;Chronic 
Pain;Atherosclerotic CVD 
(ASHCVD); Suicide 
Ethanol and 
Cyclobenzaprine 
Intoxication 
19 24 M CAUCASIAN 18.5 DepNOS 
Depressive Disorder NOS;Alcohol 
Intoxication;Deferred;Juraj DB 
Tentative Dx;Other (Specify); Accident Multiple Injuries 
20 46 M 
AFRICAN 
AMERICAN 12 PTSD 
PTSD;Alcohol 
Intoxication;Deferred;Juraj DB 
Tentative Dx;Other (Specify); Accident Multiple Injuries 
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21 58 F CAUCASIAN 33.5 PTSD 
MDD; Recurrent; with 
Psychotic;PTSD;Alcohol 
Dependence;Polysubstance 
Abuse;Polysubstance 
Intoxication;Deferred;Hypertension;
Asthma; 
unspecified;Obesity;Cirrhosis; 
alcoholic;Other (Specify); Suicide 
Hydrocodone and 
Alcohol 
Intoxication 
22 44 F 
AFRICAN 
AMERICAN 26 Control 
No Diagnosis on Axis 
1;Deferred;Other 
(Specify);Atherosclerotic CVD 
(ASHCVD);  Natural Meningitis 
23 36 F CAUCASIAN 35 MDD 
MDD; Single;Panic w/o 
Agoraphobia;Polysubstance 
Dependence;Polysubstance 
Intoxication;Deferred;Juraj DB 
Tentative Dx;Chronic Pulmonary 
Disease (COPD);Asthma; 
unspecified;Obesity;Other 
(Specify);Chronic Pain; Accident 
Morphine and 
Quetiapine 
Intoxication 
24 48 M CAUCASIAN 31.5 MDD 
MDD; Recurrent; without 
Psychotic;Alcohol 
Dependence;Alcohol 
Intoxication;Polysubstance 
Intoxication;Deferred;Juraj DB 
Tentative Dx;Hypertension;Obesity; Undetermined 
Mixed Drug 
(Diphenhydramine 
and Oxycodone) 
and Alcohol 
Intoxication 
25 43 M CAUCASIAN 26.5 DepNOS 
Depressive Disorder NOS;Alcohol 
Dependence;Deferred;Juraj DB 
Tentative Dx;Hypertension;Other 
(Specify);Mitral valve prolapse 
(MVP); Natural 
Cardiac 
Arrhythmia; 
Cardiomegaly and 
Mitral Valve 
Prolapse 
26 53 M CAUCASIAN 29.5 PTSD 
MDD; Recurrent; without 
Psychotic;PTSD;Opioid 
Intoxication;Polysubstance 
Dependence;Deferred;Juraj DB 
Tentative Dx;Hypertension;Other Undetermined 
Heroin 
intoxication and 
cocaine use 
  
3
8 
(Specify);Chronic Pain;Arthritis; 
unspecified; 
27 45 M 
AFRICAN 
AMERICAN 27.5 DepNOS 
Depressive Disorder NOS;Obsessive-
Compulsive;Juraj DB Tentative 
Dx;Contusion(s); cerebral; Suicide 
Intraoral Gunshot 
Wound 
28 53 M CAUCASIAN 28 Control 
No Diagnosis on Axis 
1;Deferred;Juraj DB Tentative 
Dx;Other (Specify); Accident Multiple Injuries 
29 48 M 
AFRICAN 
AMERICAN 28 MDD 
MDD; Single;Alcohol 
Dependence;Deferred;Juraj DB 
Tentative Dx;Hypertension;Other 
(Specify);Atherosclerotic CVD 
(ASHCVD);Emphysema;Diabetes 
Mellitus; Type II (Non-IDDM); Natural 
Atherosclerotic 
cardiovascular 
disease 
30 30 M CAUCASIAN 31 PTSD 
MDD; Recurrent; without 
Psychotic;PTSD;Alcohol 
Dependence;Deferred;Juraj DB 
Tentative Dx;Other (Specify); Suicide 
Contact Gunshot 
Wound of Head 
31 39 M CAUCASIAN 32 Control 
No Diagnosis on Axis 
1;Deferred;Juraj DB Tentative 
Dx;Other (Specify); Natural 
Cardiac 
Arrhythmia; 
Myocardial 
Fibrosis 
32 63 M CAUCASIAN 48 PTSD 
MDD; Recurrent; without 
Psychotic;PTSD;Polysubstance 
Abuse;Deferred;Juraj DB Tentative 
Dx;Hypertension;Diabetes Mellitus; 
Type I; (IDDM);Obesity;Other 
(Specify);Hypothyroidism; Suicide 
Intraoral Gunshot 
Wound 
33 48 M 
AFRICAN 
AMERICAN 24.5 MDD 
MDD; Single;Deferred;Juraj DB 
Tentative 
Dx;Hypertension;Obesity;Diabetes 
Mellitus; Type II (Non-IDDM); Suicide 
Shotgun Wound to 
the Chest 
34 61 M CAUCASIAN 31 DepNOS 
Depressive Disorder NOS;Alcohol 
Dependence;Opioid Undetermined 
Mixed Narcotic 
(Free Morphine 
  
3
9 
Intoxication;Deferred;Juraj DB 
Tentative Dx;Cirrhosis; alcoholic; 
and Methadone) 
Intoxication 
35 22 M 
AFRICAN 
AMERICAN 33 MDD 
MDD; Recurrent; without 
Psychotic;Alcohol 
Intoxication;Deferred;Juraj DB 
Tentative Dx;Asthma; 
unspecified;Obesity; Accident Multiple Injuries 
36 40 M CAUCASIAN 24.5 Control 
No Diagnosis on Axis 
1;Deferred;Juraj DB Tentative 
Dx;Obesity;Atherosclerotic CVD 
(ASHCVD); Natural 
Atherosclerotic 
Cardiovascular 
Disease 
37 50 M 
AFRICAN 
AMERICAN 28 Control 
No Diagnosis on Axis 
1;Deferred;Juraj DB Tentative 
Dx;Hypertension;Atherosclerotic 
CVD (ASHCVD); Natural 
Atherosclerotic 
Cardiovascular 
Disease 
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Tissue Collection and Preparation 
After the time of death of subjects, brain tissue was removed promptly in 
order to prevent potential tissue damage. After removal and freezing of tissue 
samples, coronal sections were removed and placed on dry ice and cut using a high 
speed drill. To prevent thawing of the tissue, cutting was halted intermittently. Cut 
sections were placed in individual plastic bags and labeled with the subject 
identification number and original brain region of cut sections. Sections were then 
placed at -80°C until required use. Of the 46 tissues collected and tested, nine were 
removed from analysis due either to improper classification of disease status (n=5) 
or to sample replication (n=4). 
RNA Isolation and cDNA Generation 
  RNA was isolated from a total of 37 subjects (6 females, 31 males; median age 
44; range, 22-63 years) for the purpose of qPCR experiments. RNA was isolated from 
dissected sections of the lateral medial prefrontal cortex, described above, utilizing the 
RNA purification protocol from Promega. For the isolation procedure, tissue samples 
were homogenized in lysis buffer based on the total mass of tissue utilized, and samples 
were homogenized using a tissue rotor until no visible fragments remained. Samples were 
then incubated for 10 minutes on ice. Following incubation, the appropriate amount of 
RNA Dilution Buffer was added at a rate of 83.5 µL of buffer for every 50 µL of lysis 
solution. Then an appropriate amount of Clearing Agent was added at the station of 25 
µL for every 10 µg of tissue. Samples were vortexes for 30 seconds, and then applied on 
a heat block at 70°C for 3 minutes, vortexes again for 30 seconds and then incubated at 
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room temperature for 5 minutes before being transferred to a provided clearing column 
and centrifuged at 12,000 x g for 2 minutes.  
Flow through from the columns were placed into individual wells of the RNA 
cartridge provided by Promega. Samples were purified using the Promega Maxwell 
instrument, utilizing the RNA purification protocol. RNA cartridges were placed into the 
Maxwell instrument in the proper orientation and elution tubes with 300 µL of nuclease 
free water were placed into the heated elution tube positions. After the completion of the 
purification protocol, samples were placed into appropriately labeled tubes via pipetting. 
RNA concentration was determined on a Bioanalyzer instrument (Agilent). Samples were 
diluted until a total concentration of 1µg/µL was achieved. RNA was stored at -80°C 
until used for further experiments.  
Reverse transcription was achieved using the High Capacity Reverse 
Transcription kit (Applied Biosystems). 10µL of RNA was heated and then procedure 
steps were performed while incubating on ice. cDNA was generated in 20µL reactions 
following the High Capacity kit procedure (Applied Biosystems). Upon completion of the 
reaction, sample volumes were adjusted to 200µL in RNase-free water, with a final 
concentration of 1ng/µL.  
Quantitative Polymerase Chain Reaction Analysis 
qPCR was performed using the Taqman Fast Advanced PCR Master Mix 
(Thermo Fisher Scientific) according to recommended multiplex protocols, with a 10µL 
final volume, using 1µL of cDNA template on a StepOne Plus instrument (Thermo Fisher 
Scientific). Cycling conditions were as follows: 95°C, 20 seconds; 40 x (95°C, 20 
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seconds; 60°C, 5 seconds). At completion of cycling conditions, samples were cooled to 
4°C and held until removed from instrument. 18s was selected as the reference gene, and 
all 54 genes were normalized to its expression. Primers were designed based on 
recommendations from Applied Biosystems and are available upon request. Of the 54 
genes tested three genes, IL-2, IL-12β, and CCL11, were removed due to poor 
dissociation curves. Threshold cycles were determined and expression levels were 
calculated using StepOne Plus Software v2.3 (Thermo Fisher Scientific). 
Statistical Analysis 
Following calculations of expression levels, normalized to the 18s gene, fold 
differences were calculated using the delta-delta-Ct methods with the assistance of 
StepOne Plus Software v2.3 (Thermo Fisher Scientific).After exporting the data, it was 
further analyzed using the Prism 7 analysis software for Macintosh (GraphPad). Data was 
presented as mean ± standard error of measurement. Differences between multiple means 
were assessed by one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc 
test. p < 0.05 was considered as statistically significant.  
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RESULTS 
 
Analysis of the Genetic Comparison between PTSD and Control Groups 
To determine if there was a significant change in expression in the genes of 
interest between the control and PTSD cases a series of qPCR experiments were 
conducted in order to determine any differences. A set of 54 genes of interest were 
identified based on evidence from previous literature. Primers were collected for each 
gene from Applied Biosystems. Of the 51 genes analyzed, two genes exhibited 
significantly altered levels of expression when compared to the control group. IL-6 
averaged a 13-fold increase in expression when compared to the control group (Figure 7). 
This indicates that IL-6 was over expressed in the prefrontal cortex, and that resulting 
downstream effects of its expression, including the production of ROS, could also be 
exacerbated. The other differentially expressed gene was NQO1, an antioxidant enzyme. 
NQO1 averaged 1/2 the expression in comparison to the control group, indicting a 
hindrance of the genes expression and the potential decrease in ability to protect against 
agents of oxidative stress.  
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Figure 7.Comparison of Genetic Expression between PTSD and Control Groups. Normalized gene expression in the PTSD and 
control groups. Bar graph indicates average level of expression, and error bars indicate 95% confidence level. * 
indicate p < 0.05.   
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Analysis of the Genetic Comparison between PTSD and Comorbidity Groups 
Due to the high rate of PTSD patients being diagnosed with comorbid disorders, 
such as major depressive disorder, I next wanted to identify potential genetic expression 
differences between the PTSD cohort and the MDD and DepNOS cohorts. Of the 51 
genes of interest that were tested, NQO1 exhibited a significantly lower level of 
expression when compared to the DepNOS cohort (p < 0.05) (Figure 8). IL-6, on the 
other hand, exhibited a significantly higher level of expression when compared to the 
MDD cohort (p < 0.05) (Figure 8). It is also of interest to note that, while the expression 
of VEGF, a downstream component influenced by the expression of IL-6, did not differ 
between PTSD and the comorbidities, its expression was significantly different between 
MDD and DepNOS (p < 0.05) (Figure 8). These results suggest a unique set of 
mechanisms in PTSD patients, namely an overactive inflammatory response and a 
hindered function of ROS removal, in comparison to commonly occurring comorbidities. 
Additionally, these results could indicate potentially different physiological symptoms 
and dysfunctions between patients diagnosed solely with PTSD and PTSD patients with 
various comorbidities.   
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Figure 8. Comparison of Genetic Expression between PTSD and Comorbidity Groups. Normalized gene expression in the PTSD and 
control groups. Bar graph indicates average level of expression, and error bars indicate 95% confidence level. * 
indicate p < 0.05.
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Analysis of the Genetic Comparison within PTSD Samples 
As mentioned previously, the diagnostic requirements for PTSD are varied, and 
diagnosis doesn’t require full compliance with all listed symptoms. Furthermore, 
numerous studies have presented, at times, contradictory results in identifying unique 
genetic aspects of PTSD. In an attempt to better understand the heterogeneity of genetic 
expression in PTSD I conducted a comparative analysis of the average expression of the 
51 genes of interest within the PTSD samples. Samples were normalized to the control 
group, and the expression of the genes of interest were measured in comparison to 
expression of 18s. While most samples exhibited tight clustering around the average 
expression, a few genes exhibited wildly varied levels of expression. A notable example 
of this can be seen in the expression variability of the transcription factor FOS, which has 
expression levels that range from the same level of expression as the control group to a 
12-fold increase in expression (Figure 9). Another notable example includes the 
inflammatory response genes IL-1β, IFN𝛾, and IL-6. IL-6, a gene that was indicated to 
have a significantly different expression in the PTSD cases, also exhibits a wide range of 
expression, from 1/10th that of the control group to a 12-fold increase in expression 
(Figure 9). A final gene of note is AQP1, which exhibits a range of expression from 1/2 
the expression of the control group to a 13-fold increase in expression (Figure 3). The 
variety in the expression levels of these genes could be a result of the heterogeneous 
mixture of cell types that made up the tissue sample the RNA was purified from, or it 
could be a result of the fundamental differences seen between PTSD cases.  
  
5
0
 
  
  
  
5
1
 
   
  
5
2
 
    
  
5
3
 
  
 
Figure 9. Comparison of Genetic Expression Variability within PTSD Samples. Normalized gene expression in the PTSD and control 
groups. Bar graph indicates average level of expression. Samples were normalized to the control group for analysis.    
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DISCUSSION 
 
 This study was conducted in order to potentially identify and validate genetic 
expression differences between PTSD patients, non-PTSD patients, and patients 
diagnosed with commonly occurring PTSD comorbidities. Tissue samples were collected 
post-mortem from military volunteers and utilized to conduct qPCR analysis on 
subsequently produced cDNA. While a number of studies have conducted qPCR 
experiments to validate experimental findings, few have utilized the technique to measure 
changes in such a large and broadly reaching panel of genes. A panel of 54 genes was 
formed based on literature that has identified inflammation and oxidative stress as 
components in PTSD pathology (Andrews et al. 2012; Spivak et al. 1997). Other genes 
incorporated onto the list include genes regulating structural integrity of the tissue, 
including junction proteins, genes associated with the blood-brain barrier, such as 
aquaporins, and genes specific to neurons and astrocytes, due to the collected evidence of 
their dysfunction in PTSD pathology (Acosta et al., 2013; Bollinger et al. 2016; 
Rosenberger et al. 2001; Shetty et al. 2014). Of the 54 genes tested, three genes were 
removed from analysis due to the presentation of poor dissociation curves. Of the genes 
analyzed, only IL-6 and NQO1 exhibited significantly different levels of expression 
between the PTSD and control or comorbid groups 
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Increased Expression of IL-6 in PTSD Subjects and its Role 
 IL-6 is an inflammatory cytokine that presents both anti- and pro-inflammatory 
functions, as well as playing roles in both acute and chronic inflammation (Gabay 2006). 
IL-6 is a key component of the acute inflammatory process, where it regulates the release 
of a number of key cytokines in response to a number of stimuli, including the presence 
of infectious agents and tissue necrosis (Scheller et al. 2011). In respect to chronic 
inflammation, IL-6 plays an important role in regulating the transition from the acute to 
chronic inflammation phases. As IL-6 expression remains elevated the inflammatory 
response transitions from the acute phase to the chronic phase, through the activation of a 
number of molecular cascades (Gabay 2006; Tanaka et al. 2014). One such example of 
this is the activation of the angiogenesis pathway through the stimulation of VEGF 
expression, leading to increased vascular permeability (Tanaka et al. 2014). IL-6 
production is promoted by the expression of NF-𝜅B, of which the RELA subunit was 
tested in this study, TNF-⍺, and IL-1β (Tanaka et al. 2014). While the expression of 
VEGF, TNF-⍺, and IL-1β are not significantly different in the PTSD samples as 
compared to the control samples, their average levels of expression are higher in the 
PTSD samples. One possible explanation for this discrepancy could be due to the mixture 
of different cell types that composed the tissue sample that was used to extract RNA. Of 
additional note is the role IL-6 plays in the regulation of epigenetic methylation. The 
expression of IL-6 functions through a number of signaling pathways, one of which 
includes the PI-3-K pathway (Hodge et al. 2007). One of the downstream effects of this 
pathway is the increased nuclear translocation of DNMT1, a methyltransferase enzyme. 
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With increased translocation, an increase in targeted gene methylation occurs, ultimately 
promoting the silencing of these targeted genes. One such targeted promoter region is 
BDNF, which exhibited increased expression upon down regulation of DNMT1 in cortical 
tissues (Sharma et al. 2008). While the expression of BDNF was not found to be 
significantly different in the PTSD group, its average expression was nearly half of the 
reported average in the control group. 
A number of studies have targeted IL-6 as a potential gene of interest, but the 
results have not been conclusive. A number of studies have found that IL-6 has a 
significantly higher level of expression, as was found in this study, while others have 
shown that it presents no change in expression in comparison to the control (Lindqvist et 
al. 2014; O’Donovan et al. 2015; Scheller et al. 2011). This difference of results is not 
particularly surprising, however, when viewing the range of expression found in our 
PTSD subject pool, ranging from no change in expression in comparison to the control 
group to a robust 12-fold increase in expression (Fig. 9). Also, while IL-6 expression is 
significantly different between PTSD and control samples, this change in expression does 
not appear to be unique to PTSD. When compared to two common comorbidities, IL-6 
expression in PTSD was significantly different when compared to MDD expression, but 
to when compared to DepNOS expression (Fig. 8). Additionally, a number of studies 
have also identified IL-6 as having an increased expression in depression disorders, 
indicating that IL-6 is not a unique factor in PTSD, but may play a role in a number of 
psychological disorders. 
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Decreased Expression of the Antioxidant Gene NQO1 in PTSD Subjects 
NQO1, the other gene identified as having a significantly different level of 
expression, is a quinone oxidoreductase that functions to remove harmful ROS from 
intracellular compartments (Zhu et al. 2012). NQO1 plays a number of other important 
biological functions, including the stabilization of p53 and anti-inflammatory functions 
(Zhu et al. 2012). NQO1 is a downstream component of the NRF2/ARE signaling 
pathway, which helps protect cells from oxidative stress damage through the reduction of 
oxidative agents. When there is an increase in oxidative agents, the NFE2L2 transcription 
factor binds to the associated ARE sequence and activates downstream components, 
including NQO1, which facilitate reduction reactions on ROS in the cell (Satoh et al. 
2006). While no studies have been conducted that have linked PTSD with NQO1 
expression, a number of studies have linked NQO1 expression with a number of cancers 
and neurodegenerative disorders (Kim et al. 2012; Hyun et al. 2012). Increased 
expression of NQO1 in cancers has been linked to increased cellular durability and 
increased protection from cellular stress responses (Hyun et al. 2012). In studies 
conducted on neurodegeneration, where inflammation and oxidative stress are key 
components of the observed pathology, the expression of NQO1 has been shown to be 
decreased, resulting in less protection from stress environments (Kim et al. 2012). The 
results from the study indicate a significantly lower expression of NQO1 in the PTSD 
samples in comparison to the control samples, in line with what is seen in 
neurodegenerative diseases (Figure. 7). The results in this study, indicating that there is 
some level of neurodegeneration in PTSD pathology, seems to correspond with staining 
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studies which have found thinning in regions of the brain associated with PTSD, 
including the prefrontal cortex and the hippocampus (O’Donovan et al. 2015; Li et al. 
2013; Logue et al. 2013; Kaminsky et al. 2015; Liu et al. 2016). One note of interest, 
however, is that the expression of the NFE2L2 transcription factor, which regulates 
NQO1 expression, was not significantly different between the control and PTSD groups 
(Figure 7). This could potentially indicate that change in NQO1 expression is specific to 
that gene, and not a result of an upstream regulator. Furthermore, in the comparison of 
NQO1 expression between PTSD and common comorbidities, NQO1 expression was 
significantly different when compared to DepNOS, but not MDD (Figure 8). While, 
separately, the decreased expression of NQO1 and the increased expression of IL-6 are 
not unique to PTSD, when taken together they are. Thus, these genes can be used to 
potentially act as a screening panel to positively identify PTSD from other similar 
comorbidities. Unlike IL-6, however, the range of NQO1 expression was not nearly as 
varied amongst the different PTSD cases, indicating that this genetic change might be 
conserved in the presentation of PTSD (Figure 9). 
Conclusions and Future Directions 
While past studies have examined changes in small collections of genes of 
interest, mostly as a way to validate their other findings, in this study we attempted to 
compare a wide range of genes across a uniform sample group. Although there were 
minor limitations to the study, most notably the limited sample size, a few genes of 
interest were found to exhibit significant changes in expression, allowing for the 
foundation for some potentially interesting future studies. One particular future direction 
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could be the comparison of gene expression not only in the prefrontal cortex, but also in 
other regions of the brain associated with PTSD, such as the hippocampus. Another 
future direction that could be approached would be to identify the mechanism behind the 
perceived changes in genetic expression, whether they be epigenetic, such as promotor 
region methylation, or sequence changes brought on by oxidative stress or other cellular 
damage. A final future direction includes staining studies utilizing these genes of interest. 
As stated in a throughout the study, RNA was produced from a heterogeneous mixture of 
cell types found in the prefrontal cortex, and as such the specific cell types that undergo 
genetic and functional changes could not be identified through this study. Obtaining a 
better understanding of the physiological changes associated with PTSD is necessary in 
order to better treat the disorder.  
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